Actinium-225 DOTATATE (RYZ101)

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

α radiation emission, SSTR2 inhibitor

Related drugs:

‹

›

SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	RYZ101 Sensitive: C3 – Early Trials RYZ101 Sensitive : C3	RYZ101 Sensitive: C3 – Early Trials RYZ101 Sensitive : C3
SSTR2 overexpression	Small Cell Lung Cancer	SSTR2 overexpression	Small Cell Lung Cancer	RYZ101 Sensitive: D – Preclinical RYZ101 Sensitive : D	RYZ101 Sensitive: D – Preclinical RYZ101 Sensitive : D

Associations
(2)